BioSpace News Archive

Adding ancillary services helps increase practice revenue and patient retention, finds Frost & Sullivan

Treatment of arthritis in canines is an estimated $1.9 billion annual market with unmet need for safe and effective oral drug

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and cleared the Investigational New Drug Application (IND) for ACH-5228, the Company’s second-generation oral factor D inhibitor.

At the 2019 American College of Rheumatology/Association of Rheumatology Professionals annual meeting in Atlanta, experts from the HSS Education Institute at Hospital for Special Surgery presented their method for developing and implementing effective educational programs for diverse patients with rheumatic conditions.

Tetra Bio-PharmaInc., (TSX-V) (OTCQB: TBPMF), a leader in drug discovery and development for cannabinoid-based therapeutics, today confirmed its regulatory strategy of its CAUMZTM (PPP011) inhalation drug product and provided additional updates on its progress with U.S. Food and Drug Administration (FDA) for an expedited review.

Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced financial results for its second fiscal quarter, ended September 30, 2019, and provided a corporate update.

Foamix Pharmaceuticals Ltd., a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, announced financial results for the three and nine months ended September 30, 2019 and provided a corporate update.

Dose-Dependent and Statistically Significant Improvement in Areal Bone Mineral Density (BMD) Over Baseline at the Lumbar Spine, as Measured by DXA, Reaching 8.8% at 12 Months in Highest Dose Cohort (p<0.001); Improvement Consistent Across All OI Subtypes Represented in Study

Global Cord Blood Corporation, China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, announced the appointment of a new independent non-executive director to the Board of Directors of the Company

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced today that it has received a Complete Response Letter (“CRL”) from the United States Food and Drug Administration (“FDA”) regarding its New Drug Application (“NDA”) for TLANDO™